top of page

BridgeBio's Neil Kumar reviews #AHA23 data and the company's pipeline and finances

Neil Kumar discusses the competitive profile he sees emerging for acoramidis, a big phase 3 that will read in ADH1 early next year, and the draw to invest in early science.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page